Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats

Abaloparatide is a novel, potent and selective activator of parathyroid hormone receptor 1 (PTHR1) under clinical development for the treatment of osteoporosis. We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats. Afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahar, Hila, Gallacher, Kyla, Downall, Julie, Nelson, Carol A., Shomali, Maysoun, Hattersley, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055567/
https://www.ncbi.nlm.nih.gov/pubmed/27395059
http://dx.doi.org/10.1007/s00223-016-0171-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055567/
https://www.ncbi.nlm.nih.gov/pubmed/27395059
http://dx.doi.org/10.1007/s00223-016-0171-1

Ejemplares similares